- Mylan subsidiary gets approval for HIV generic under PEPFAR
- FDA approves Merck's Gardasil for prevention of anal cancer
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Walgreens launches high-impact push in support of World AIDS Day campaign
PITTSBURGH — Under the President's Emergency Plan for AIDS Relief, the Food and Drug Administration has given tentative approval to a generic HIV and AIDS drug made by Mylan, the company said.
The drug maker's Mylan Labs subsidiary received tentative approval for atazanavir sulfate and ritonavir tablets in the 300-mg/100-mg strength. The FDA's tentative approval of the drug under PEPFAR means it will be eligible for purchase in certain developing countries.
Mylan said the drug was the first heat-stable, fixed-dose combination of the two drugs. The World Health Organization also "pre-qualified" the drug as a second-line treatment option for HIV and AIDS, the company said.
Atazanavir sulfate is a generic version of Bristol-Myers Squibb's Reyataz, while ritonavir is a generic version of Abbott Labs' Norvir.